Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer
Phase II Study of FOLFOX With Bevacizumab (Avastin(TM)) in Metastatic or Unresectable Gastroesophageal and Gastric Cancer
Status: Enrolling
Updated:  4/28/2009
Medical Oncology & Hematology PC
mi
from
Hamden, CT
FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer
Phase II Study of FOLFOX With Bevacizumab (Avastin(TM)) in Metastatic or Unresectable Gastroesophageal and Gastric Cancer
Status: Enrolling
Updated: 4/28/2009
Medical Oncology & Hematology PC
mi
from
Hamden, CT
Click here to add this to my saved trials
FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer
Phase II Study of FOLFOX With Bevacizumab (Avastin(TM)) in Metastatic or Unresectable Gastroesophageal and Gastric Cancer
Status: Enrolling
Updated:  4/28/2009
Yale University School of Medicine
mi
from
New Haven, CT
FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer
Phase II Study of FOLFOX With Bevacizumab (Avastin(TM)) in Metastatic or Unresectable Gastroesophageal and Gastric Cancer
Status: Enrolling
Updated: 4/28/2009
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer
A Dose Escalation Study of Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  5/13/2009
Yale University School of Medicine
mi
from
New Haven, CT
Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer
A Dose Escalation Study of Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 5/13/2009
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer
Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer
Status: Enrolling
Updated:  5/13/2009
University of Florida College of Medicine
mi
from
Gainesville, FL
Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer
Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer
Status: Enrolling
Updated: 5/13/2009
University of Florida College of Medicine
mi
from
Gainesville, FL
Click here to add this to my saved trials
Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer
Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer
Status: Enrolling
Updated:  5/13/2009
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer
Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer
Status: Enrolling
Updated: 5/13/2009
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer
Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer
Status: Enrolling
Updated:  5/13/2009
Beth Israel Med Ctr
mi
from
New York, NY
Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer
Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer
Status: Enrolling
Updated: 5/13/2009
Beth Israel Med Ctr
mi
from
New York, NY
Click here to add this to my saved trials
Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer
Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer
Status: Enrolling
Updated:  5/13/2009
Duke Univ Med Ctr
mi
from
Durham, NC
Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer
Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer
Status: Enrolling
Updated: 5/13/2009
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer
Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer
Status: Enrolling
Updated:  5/13/2009
Temple University Hospital
mi
from
Philadelphia, PA
Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer
Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer
Status: Enrolling
Updated: 5/13/2009
Temple University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer
Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer
Status: Enrolling
Updated:  5/13/2009
M.D. Anderson Cancer Center
mi
from
Houston, TX
Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer
Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer
Status: Enrolling
Updated: 5/13/2009
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Clinical Study of GP73 as a Hepatocellular Carcinoma (HCC) Tumor Mark
A Clinical Study of GP73 as a HCC Early Tumor Mark
Status: Enrolling
Updated:  5/14/2009
University of Chicago
mi
from
Chicago, IL
A Clinical Study of GP73 as a Hepatocellular Carcinoma (HCC) Tumor Mark
A Clinical Study of GP73 as a HCC Early Tumor Mark
Status: Enrolling
Updated: 5/14/2009
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors
A Phase I Open Label Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of SF1126, A PI3 Kinase (PI3K) Inhibitor, Given Twice Weekly By IV Infusion To Patients With Advanced or Metastatic Tumors
Status: Enrolling
Updated:  5/21/2009
Scottsdale Clinical Research Institute
mi
from
Scottsdale, AZ
A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors
A Phase I Open Label Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of SF1126, A PI3 Kinase (PI3K) Inhibitor, Given Twice Weekly By IV Infusion To Patients With Advanced or Metastatic Tumors
Status: Enrolling
Updated: 5/21/2009
Scottsdale Clinical Research Institute
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors
A Phase I Open Label Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of SF1126, A PI3 Kinase (PI3K) Inhibitor, Given Twice Weekly By IV Infusion To Patients With Advanced or Metastatic Tumors
Status: Enrolling
Updated:  5/21/2009
Arizona Cancer Center
mi
from
Tucson, AZ
A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors
A Phase I Open Label Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of SF1126, A PI3 Kinase (PI3K) Inhibitor, Given Twice Weekly By IV Infusion To Patients With Advanced or Metastatic Tumors
Status: Enrolling
Updated: 5/21/2009
Arizona Cancer Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors
A Phase I Open Label Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of SF1126, A PI3 Kinase (PI3K) Inhibitor, Given Twice Weekly By IV Infusion To Patients With Advanced or Metastatic Tumors
Status: Enrolling
Updated:  5/21/2009
Emory Winship Cancer Institute
mi
from
Atlanta, GA
A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors
A Phase I Open Label Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of SF1126, A PI3 Kinase (PI3K) Inhibitor, Given Twice Weekly By IV Infusion To Patients With Advanced or Metastatic Tumors
Status: Enrolling
Updated: 5/21/2009
Emory Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors
A Phase I Open Label Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of SF1126, A PI3 Kinase (PI3K) Inhibitor, Given Twice Weekly By IV Infusion To Patients With Advanced or Metastatic Tumors
Status: Enrolling
Updated:  5/21/2009
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
A Dose Escalation Study of SF1126, a PI3 Kinase (PI3K) Inhibitor, Given By Intravenous (IV) Infusion in Patients With Solid Tumors
A Phase I Open Label Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation Study of SF1126, A PI3 Kinase (PI3K) Inhibitor, Given Twice Weekly By IV Infusion To Patients With Advanced or Metastatic Tumors
Status: Enrolling
Updated: 5/21/2009
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Prospective Evaluation of Intrafractional and Interfractional Cervical Motion During External Beam Radiation for Intact Cervical Cancer by the Calypso® 4D Localization System™
Prospective Evaluation of Intrafractional and Interfractional Cervical Motion During External Beam Radiation for Intact Cervical Cancer by the Calypso® 4D Localization System™
Status: Enrolling
Updated:  5/21/2009
Emory University
mi
from
Atlanta, GA
Prospective Evaluation of Intrafractional and Interfractional Cervical Motion During External Beam Radiation for Intact Cervical Cancer by the Calypso® 4D Localization System™
Prospective Evaluation of Intrafractional and Interfractional Cervical Motion During External Beam Radiation for Intact Cervical Cancer by the Calypso® 4D Localization System™
Status: Enrolling
Updated: 5/21/2009
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer
A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer
Status: Enrolling
Updated:  5/27/2009
Northwest Alabama Cancer Center, PC
mi
from
Muscle Shoals, AL
A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer
A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer
Status: Enrolling
Updated: 5/27/2009
Northwest Alabama Cancer Center, PC
mi
from
Muscle Shoals, AL
Click here to add this to my saved trials
A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer
A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer
Status: Enrolling
Updated:  5/27/2009
UCSD Moores Cancer Center
mi
from
La Jolla, CA
A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer
A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer
Status: Enrolling
Updated: 5/27/2009
UCSD Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer
A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer
Status: Enrolling
Updated:  5/27/2009
Signal Point Hematology/Oncology
mi
from
Middletown, OH
A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer
A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer
Status: Enrolling
Updated: 5/27/2009
Signal Point Hematology/Oncology
mi
from
Middletown, OH
Click here to add this to my saved trials
A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer
A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer
Status: Enrolling
Updated:  5/27/2009
Hospital Universitario Austral
mi
from
Buenos Aires,
A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer
A Bioequivalence Study of Docetaxel for Injectable Emulsion (ANX-514) in Patients With Advanced Cancer
Status: Enrolling
Updated: 5/27/2009
Hospital Universitario Austral
mi
from
Buenos Aires,
Click here to add this to my saved trials
Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome
Mechanism and Response of Thymoglobulin in Patients With Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  6/1/2009
UCLA Oncology Center
mi
from
Los Angeles, CA
Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome
Mechanism and Response of Thymoglobulin in Patients With Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 6/1/2009
UCLA Oncology Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome
Mechanism and Response of Thymoglobulin in Patients With Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  6/1/2009
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome
Mechanism and Response of Thymoglobulin in Patients With Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 6/1/2009
H. Lee Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome
Mechanism and Response of Thymoglobulin in Patients With Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  6/1/2009
Cleveland Clinic Foundation - Case Western University
mi
from
Cleveland, OH
Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome
Mechanism and Response of Thymoglobulin in Patients With Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 6/1/2009
Cleveland Clinic Foundation - Case Western University
mi
from
Cleveland, OH
Click here to add this to my saved trials
Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome
Mechanism and Response of Thymoglobulin in Patients With Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated:  6/1/2009
Penn State University
mi
from
Hershey, PA
Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome
Mechanism and Response of Thymoglobulin in Patients With Myelodysplastic Syndrome (MDS)
Status: Enrolling
Updated: 6/1/2009
Penn State University
mi
from
Hershey, PA
Click here to add this to my saved trials
Efficacy and Safety of Sublingual Fentanyl Tablets in Treatment of Breakthrough Pain in Cancer Patients.
A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of EN3267 for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients.
Status: Enrolling
Updated:  6/2/2009
Carolinas Pain Institute
mi
from
Winston-Salem, NC
Efficacy and Safety of Sublingual Fentanyl Tablets in Treatment of Breakthrough Pain in Cancer Patients.
A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of EN3267 for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients.
Status: Enrolling
Updated: 6/2/2009
Carolinas Pain Institute
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers
A Phase I Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane (Paclitaxel Protein-Bound Particles) in Advanced Solid Cancers
Status: Enrolling
Updated:  6/5/2009
Yale Comprehensive Cancer Center at Yale University School of Medicine
mi
from
New Haven, CT
A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers
A Phase I Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane (Paclitaxel Protein-Bound Particles) in Advanced Solid Cancers
Status: Enrolling
Updated: 6/5/2009
Yale Comprehensive Cancer Center at Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer
A Phase II Study of Rapamycin (Rapamune, Sirolimus) and Trastuzumab (Herceptin) for Patients With HER-2 Receptor Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  6/5/2009
Bridgeport Hospital
mi
from
Bridgeport, CT
A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer
A Phase II Study of Rapamycin (Rapamune, Sirolimus) and Trastuzumab (Herceptin) for Patients With HER-2 Receptor Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 6/5/2009
Bridgeport Hospital
mi
from
Bridgeport, CT
Click here to add this to my saved trials
A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer
A Phase II Study of Rapamycin (Rapamune, Sirolimus) and Trastuzumab (Herceptin) for Patients With HER-2 Receptor Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  6/5/2009
Yale Comprehensive Cancer Center at Yale University School of Medicine
mi
from
New Haven, CT
A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer
A Phase II Study of Rapamycin (Rapamune, Sirolimus) and Trastuzumab (Herceptin) for Patients With HER-2 Receptor Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 6/5/2009
Yale Comprehensive Cancer Center at Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer
Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated:  6/5/2009
Yale University, Yale Cancer Center
mi
from
New Haven, CT
Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer
Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer
Status: Enrolling
Updated: 6/5/2009
Yale University, Yale Cancer Center
mi
from
New Haven, CT
Click here to add this to my saved trials
Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers
Phase I Dose Finding Study of the Orally Bioavailable Platinum Analog Satraplatin in Combination With Abraxane (Paclitaxel Protein-Bound Particles) in Advanced Cancers
Status: Enrolling
Updated:  6/5/2009
Yale University, Comprehensive Cancer Center
mi
from
New Haven, CT
Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers
Phase I Dose Finding Study of the Orally Bioavailable Platinum Analog Satraplatin in Combination With Abraxane (Paclitaxel Protein-Bound Particles) in Advanced Cancers
Status: Enrolling
Updated: 6/5/2009
Yale University, Comprehensive Cancer Center
mi
from
New Haven, CT
Click here to add this to my saved trials
HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer
A Dose-Escalating and Phase II Clinical Trial of the Histone Deacetylase (HDAC) Inhibitor Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA, ZolinzaTM) in Combination With Capecitabine (XelodaTM) Using a New Weekly Dose Regimen for Advanced Breast Cancer
Status: Enrolling
Updated:  6/5/2009
Yale University School of Medicine
mi
from
New Haven, CT
HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer
A Dose-Escalating and Phase II Clinical Trial of the Histone Deacetylase (HDAC) Inhibitor Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA, ZolinzaTM) in Combination With Capecitabine (XelodaTM) Using a New Weekly Dose Regimen for Advanced Breast Cancer
Status: Enrolling
Updated: 6/5/2009
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Low Dose Radiation Therapy as Chemosensitizer in GI/ Ovarian Tumors
GCC 0319: A Phase I/II Study of Low-Dose Upper Abdominal Radiation Therapy (UART) or Whole (W) ART as Chemosensitizer in Patients With Locally Advanced or Metastatic Tumors of the Gastrointestinal Tract or Ovary
Status: Enrolling
Updated:  6/29/2009
University of Maryland & Baltimore VA medical centre
mi
from
Baltimore, MD
Low Dose Radiation Therapy as Chemosensitizer in GI/ Ovarian Tumors
GCC 0319: A Phase I/II Study of Low-Dose Upper Abdominal Radiation Therapy (UART) or Whole (W) ART as Chemosensitizer in Patients With Locally Advanced or Metastatic Tumors of the Gastrointestinal Tract or Ovary
Status: Enrolling
Updated: 6/29/2009
University of Maryland & Baltimore VA medical centre
mi
from
Baltimore, MD
Click here to add this to my saved trials
Smoking Cessation Treatment for Head and Neck Cancer Patients
Smoking Cessation Treatment for Head and Neck Cancer Patients
Status: Enrolling
Updated:  7/1/2009
Yale University School of Medicine
mi
from
New Haven, CT
Smoking Cessation Treatment for Head and Neck Cancer Patients
Smoking Cessation Treatment for Head and Neck Cancer Patients
Status: Enrolling
Updated: 7/1/2009
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors
A Phase I Study of Gemcitabine, Capecitabine and ZD6474 (ZACTIMA) in Patients With Advanced Solid Tumors With an Expanded Cohort of Patients With Biliary or Pancreatic Malignancies.
Status: Enrolling
Updated:  7/2/2009
University of Colorado Denver
mi
from
Aurora, CO
Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors
A Phase I Study of Gemcitabine, Capecitabine and ZD6474 (ZACTIMA) in Patients With Advanced Solid Tumors With an Expanded Cohort of Patients With Biliary or Pancreatic Malignancies.
Status: Enrolling
Updated: 7/2/2009
University of Colorado Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
Dendritic Cell Vaccine for Head and Neck Cancer
0608 GCC:Phase I Study of Intra-Tumoral Injection of Dendritic Cells for the Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  7/8/2009
University of Maryland Dept. of Otorhinolaryngology
mi
from
Baltimore, MD
Dendritic Cell Vaccine for Head and Neck Cancer
0608 GCC:Phase I Study of Intra-Tumoral Injection of Dendritic Cells for the Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 7/8/2009
University of Maryland Dept. of Otorhinolaryngology
mi
from
Baltimore, MD
Click here to add this to my saved trials
Four Doses of MAGE Vaccine for Patients With Squamous Cell Carcinoma of the Head and Neck
A Phase 1 Open Label, Dose Escalation Study to Evaluate the Effect of Four Doses of MAGE-A3/HPV 16 Trojan Peptides 0001 and 0002 Administered Subcutaneously
Status: Enrolling
Updated:  7/8/2009
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Four Doses of MAGE Vaccine for Patients With Squamous Cell Carcinoma of the Head and Neck
A Phase 1 Open Label, Dose Escalation Study to Evaluate the Effect of Four Doses of MAGE-A3/HPV 16 Trojan Peptides 0001 and 0002 Administered Subcutaneously
Status: Enrolling
Updated: 7/8/2009
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers
A Phase I Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers
Status: Enrolling
Updated:  7/15/2009
Yale University School of Medicine
mi
from
New Haven, CT
Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers
A Phase I Study of the Weekly Oral RAD001 in Combination With Oral Topotecan in Patients With Advanced or Recurrent Endometrial Cancers
Status: Enrolling
Updated: 7/15/2009
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
A Pilot Study of Ultra Rapid Opioid Rotation and Titration of Oxymorphone
A Pilot Study of Ultra Rapid Opioid Rotation and Titration of Oxymorphone
Status: Enrolling
Updated:  7/23/2009
Mount Sinai School of Medicine
mi
from
New York, NY
A Pilot Study of Ultra Rapid Opioid Rotation and Titration of Oxymorphone
A Pilot Study of Ultra Rapid Opioid Rotation and Titration of Oxymorphone
Status: Enrolling
Updated: 7/23/2009
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
A Randomized Trial to Determine if Vitamin B6 Can Prevent Hand and Foot Syndrome in Cancer Patients Treated With Capecitabine Chemotherapy
Status: Enrolling
Updated:  8/3/2009
John H. Stroger, Jr. Hospital of Cook County
mi
from
Chicago, IL
A Randomized Trial to Determine if Vitamin B6 Can Prevent Hand and Foot Syndrome in Cancer Patients Treated With Capecitabine Chemotherapy
Status: Enrolling
Updated: 8/3/2009
John H. Stroger, Jr. Hospital of Cook County
mi
from
Chicago, IL
Click here to add this to my saved trials
Evaluation of Intra-operative Ultrasound Contrast Enhancement in the Evaluation of Liver Tumors
Evaluation of Intra-operative Ultrasound Contrast Enhancement in the Evaluation of Liver Tumors
Status: Enrolling
Updated:  8/6/2009
Norton Healthcare
mi
from
Louisville, KY
Evaluation of Intra-operative Ultrasound Contrast Enhancement in the Evaluation of Liver Tumors
Evaluation of Intra-operative Ultrasound Contrast Enhancement in the Evaluation of Liver Tumors
Status: Enrolling
Updated: 8/6/2009
Norton Healthcare
mi
from
Louisville, KY
Click here to add this to my saved trials
Evaluation of Intra-operative Ultrasound Contrast Enhancement in the Evaluation of Liver Tumors
Evaluation of Intra-operative Ultrasound Contrast Enhancement in the Evaluation of Liver Tumors
Status: Enrolling
Updated:  8/6/2009
University of Louisville Hospital
mi
from
Louisville, KY
Evaluation of Intra-operative Ultrasound Contrast Enhancement in the Evaluation of Liver Tumors
Evaluation of Intra-operative Ultrasound Contrast Enhancement in the Evaluation of Liver Tumors
Status: Enrolling
Updated: 8/6/2009
University of Louisville Hospital
mi
from
Louisville, KY
Click here to add this to my saved trials
Increasing Primary Care Physician Colorectal Cancer Screening Rates
Increasing Primary Care Physician Colorectal Cancer Screening Rates
Status: Enrolling
Updated:  8/7/2009
University of Pennsylvania School of Medicine
mi
from
Philadelphia, PA
Increasing Primary Care Physician Colorectal Cancer Screening Rates
Increasing Primary Care Physician Colorectal Cancer Screening Rates
Status: Enrolling
Updated: 8/7/2009
University of Pennsylvania School of Medicine
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer
A Phase II Study of Preoperative Dose-dense (dd) Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel (T) With Bevacizumab in ER+ and/or PR+, HER2-negative Operable Breast Cancer
Status: Enrolling
Updated:  8/24/2009
Dana-Farber Cancer Institute
mi
from
Boston, MA
Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer
A Phase II Study of Preoperative Dose-dense (dd) Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel (T) With Bevacizumab in ER+ and/or PR+, HER2-negative Operable Breast Cancer
Status: Enrolling
Updated: 8/24/2009
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer
A Phase II Study of Preoperative Dose-dense (dd) Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel (T) With Bevacizumab in ER+ and/or PR+, HER2-negative Operable Breast Cancer
Status: Enrolling
Updated:  8/24/2009
Massachusetts General Hospital
mi
from
Boston, MA
Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer
A Phase II Study of Preoperative Dose-dense (dd) Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel (T) With Bevacizumab in ER+ and/or PR+, HER2-negative Operable Breast Cancer
Status: Enrolling
Updated: 8/24/2009
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer
A Phase II Study of Preoperative Dose-dense (dd) Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel (T) With Bevacizumab in ER+ and/or PR+, HER2-negative Operable Breast Cancer
Status: Enrolling
Updated:  8/24/2009
Dana-Farber at Faulkner Hospital
mi
from
Boston, MA
Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer
A Phase II Study of Preoperative Dose-dense (dd) Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel (T) With Bevacizumab in ER+ and/or PR+, HER2-negative Operable Breast Cancer
Status: Enrolling
Updated: 8/24/2009
Dana-Farber at Faulkner Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer
A Phase II Study of Preoperative Dose-dense (dd) Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel (T) With Bevacizumab in ER+ and/or PR+, HER2-negative Operable Breast Cancer
Status: Enrolling
Updated:  8/24/2009
New Hampshire Oncology-Hematology PA
mi
from
Hooksett, NH
Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer
A Phase II Study of Preoperative Dose-dense (dd) Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel (T) With Bevacizumab in ER+ and/or PR+, HER2-negative Operable Breast Cancer
Status: Enrolling
Updated: 8/24/2009
New Hampshire Oncology-Hematology PA
mi
from
Hooksett, NH
Click here to add this to my saved trials
A Phase I Cancer Vaccine Study for Patients With Metastatic Breast Cancer
A Phase I Vaccine Study With Autologous Dendritic Cells Loaded With Oncofetal Antigen/iLRP in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated:  8/25/2009
Quantum Immunologics
mi
from
Mobile, AL
A Phase I Cancer Vaccine Study for Patients With Metastatic Breast Cancer
A Phase I Vaccine Study With Autologous Dendritic Cells Loaded With Oncofetal Antigen/iLRP in Patients With Metastatic Breast Cancer
Status: Enrolling
Updated: 8/25/2009
Quantum Immunologics
mi
from
Mobile, AL
Click here to add this to my saved trials
Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer
Phase I/II Dose Escalation Trial of Induction and Concomitant Erlotinib and Celecoxib With Radiation Therapy for Treatment of Poor Prognosis Head and Neck Cancer, Including Reirradiation
Status: Enrolling
Updated:  9/1/2009
Mount Sinai School of Medicine
mi
from
New York, NY
Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck Cancer
Phase I/II Dose Escalation Trial of Induction and Concomitant Erlotinib and Celecoxib With Radiation Therapy for Treatment of Poor Prognosis Head and Neck Cancer, Including Reirradiation
Status: Enrolling
Updated: 9/1/2009
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Impact of a Novel Patient Educational Booklet on Colonoscopy Quality
Impact of a Novel Patient Educational Booklet on Colonoscopy Quality
Status: Enrolling
Updated:  9/10/2009
West Los Angeles VA Healthcare Center
mi
from
Los Angeles, CA
Impact of a Novel Patient Educational Booklet on Colonoscopy Quality
Impact of a Novel Patient Educational Booklet on Colonoscopy Quality
Status: Enrolling
Updated: 9/10/2009
West Los Angeles VA Healthcare Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01)
Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01)
Status: Enrolling
Updated:  9/17/2009
Mount Sinai Medical Center
mi
from
Miami Beach, FL
Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01)
Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01)
Status: Enrolling
Updated: 9/17/2009
Mount Sinai Medical Center
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Medical Treatment of "High-Risk" Neurofibromas
Medical Treatment of "High-Risk" Neurofibromas in Patients With Type 1 Neurofibromatosis: A Clinical Trial of Sequential Medical Therapies
Status: Enrolling
Updated:  9/22/2009
Helen DeVos Children's Hospital
mi
from
Grand Rapids, MI
Medical Treatment of "High-Risk" Neurofibromas
Medical Treatment of "High-Risk" Neurofibromas in Patients With Type 1 Neurofibromatosis: A Clinical Trial of Sequential Medical Therapies
Status: Enrolling
Updated: 9/22/2009
Helen DeVos Children's Hospital
mi
from
Grand Rapids, MI
Click here to add this to my saved trials